Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
BioXcel Therapeutics, Inc. (BTAI) had Free Cash Flow per Share of $-0.50 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.21M |
|
$-12.69M |
|
$0.28M |
|
$-0.08M |
|
$10.43M |
|
$-10.22M |
|
$-2.47M |
|
$-12.69M |
|
$-12.69M |
|
$-12.69M |
|
$-12.69M |
|
$-12.69M |
|
$-12.69M |
|
$-10.22M |
|
$-10.16M |
|
23.57M |
|
23.57M |
|
$-0.54 |
|
$-0.54 |
|
| Balance Sheet Financials | |
$33.91M |
|
$0.12M |
|
$0.12M |
|
$34.02M |
|
$54.99M |
|
$77.86M |
|
$84.57M |
|
$139.57M |
|
$-105.54M |
|
$-105.54M |
|
$-105.54M |
|
27.07M |
|
| Cash Flow Statement Financials | |
$-11.81M |
|
-- |
|
$0.23M |
|
$28.76M |
|
$17.18M |
|
$-11.58M |
|
$0.43M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.62 |
|
-- |
|
-- |
|
-2.81 |
|
-0.95 |
|
-37.38% |
|
-4962.62% |
|
-4962.62% |
|
-- |
|
-6160.68% |
|
-6160.68% |
|
$-11.81M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
0.57 |
|
0.95 |
|
94.37 |
|
12.02% |
|
12.02% |
|
-37.30% |
|
45.84% |
|
$-3.90 |
|
|
Free Cash Flow per Share |
$-0.50 |
$-0.50 |
|